{"prompt": "['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'preparations, over-the-counter medications, vitamins, and minerals. Any changes in medications', 'during the study will also be recorded on the eCRF.', 'Local standard treatment of hemophilia is considered to be, but not limited to, IV infusion of', \"FVIII or FIX concentrates. Use of these concentrates will be captured in the patient's eDiary.\", 'Use of prothrombin complex concentrates for bleeding episode management is not permitted.', 'Antifibrinolytics may be used as single agents, but may not be used in combination with factor', 'concentrates or BPA.', '6.3.1.', 'Management of Bleeding Episodes', 'The occurrence of bleeding episodes is a typical characteristic of hemophilia; [2, 5, 6] bleeding', 'episodes will be recorded as an efficacy assessment of fitusiran and will not be considered as', 'AEs unless the criteria for SAEs are met (see AEs definitions in Section 7.5.6.1). Bleeding', 'episodes will be recorded in the eDiary. For bleeding episodes in which there was no factor', 'concentrate infusion or other type of intervention employed, the reason the bleeding episodes', 'were untreated will be recorded in the eDiary (see Section 7.2.1).', 'Investigators will establish and provide instructions for an individualized bleed management plan', 'based on the guidelines in Table 4 for each patient.', 'The bleed management plan should be reviewed by the Investigator or designee with the patient', 'at each clinic visit (and via telephone contact every 2 weeks between clinic visits) and updated as', 'necessary.', 'Doses of rFVIIa and aPCC are included for completeness. It is expected that these non-inhibitor', 'patients will be routinely managed with FVIII and FIX.', '6.3.1.1.', 'Bleeding Episode Management Recommendations for Patients in the On-', 'Demand Treatment Arm (Patients Not Receiving Fitusiran)', 'For patients not receiving fitusiran (on-demand arm), bleeding management therapy with factor', 'concentrate will be managed based on the local standard practice for treating hemophilia patients', 'without inhibitors, as routinely administered by the physician. Where clinical circumstances', 'allow, it is recommended that the patient contact the Investigator for all events that may be', 'suspected to be or characteristic of a bleeding episode. If adequate hemostasis does not occur', 'after two doses of factor concentrate, the patient should contact the site for further instruction. If', \"the patient feels the need to administer doses higher than the patient's bleeding episode\", 'management plan recommends, or at a higher frequency, it is recommended that the patient', 'contact the site. See Section 7.2.1 regarding patient use of the eDiary and site alerts that will', 'assist in this process.', '6.3.1.2.', 'Bleeding Episode Management Recommendations for Patients in the Fitusiran', 'Treatment Arm', 'Given the mechanism of action and pharmacodynamic profile of fitusiran, the factor concentrate', 'dose necessary to safely and effectively treat breakthrough bleeding episodes will be lower than', 'standardly prescribed. This is supported by data from the Phase 1 study in which bleed events', 'were managed with factor and BPA, as well as additional modeling and ex vivo spiking data.', 'Property of the Sanofi Group - strictly confidential', '46', '(electronic 1.0)']['SAR439774 (formerly ALN-AT3SC) (fitusiran)', 'Clinical Study Protocol ALN-AT3SC-004', '(Sanofi Genzyme EFC14769)', '27 Jun 2018', 'More detailed information on the clinical experience in bleeding episode management in Phase 1', 'and Phase 1/2 fitusiran studies, as well as supportive nonclinical studies is provided in the', \"Investigator's Brochure.\", 'After administration of fitusiran, AT lowering will be progressing toward therapeutic levels. As', 'quickly as 7 days after the initial fitusiran dose, the majority of patients will have AT levels at or', 'below 60% residual activity. By 14 days after dosing, it is expected that 94% of patients will', 'have AT lowering of >50%, with a median value of 66.8%. Based on these AT kinetics, it is', 'recommended that patients continue with their standard factor regimens for the first 7 days', 'following initiation of fitusiran dosing, with institution of the protocol-specific bleed', 'management guidelines with reduced factor or BPA at Day 8 and beyond (Table 4).', 'Patients on fitusiran, will be provided a bleed management plan with appropriate dosing of factor', 'concentrates for use during Day 1 through 7, as well as a bleed management plan with dosing for', 'Day 8 and beyond. Thereafter the bleed management plan will be reviewed and updated at', 'monthly visits, and new written plans provided to the patient if dosing changes.', 'Importantly, during the treatment period, patients should not use factor concentrates or other', 'hemostatic agents as prophylaxis for bleeding episode prevention, including doses related to', 'anticipated hemostatic challenges such as physical activity. For prophylaxis of bleeding', 'episodes in patients who require operative procedures see Section 6.6.', 'Property of the Sanofi Group - strictly confidential', '47', '(electronic 1.0)']\n\n###\n\n", "completion": "END"}